In the last decade, we have observed an increased public and scientific interest in the clinical applications of medical cannabis. Currently, the application of cannabinoids in cancer patients is mainly due to their analgesic and anti-emetic effects.
Cannabis has been used to treat pain for thousands of years. However, since the early part of the 20th century, laws restricting cannabis use have limited its evaluation using modern scientific criteria.
Medical cannabis, or cannabinoid-based products, continues to grow in popularity globally, driving the evolution of regulatory access frameworks; cancer patients and caregivers often rely on guidance from their physicians regarding cannabinoid-based treatments. But the majority of healthcare practitioners still feel unprepared and insufficiently informed to make reasonable, evidence-based recommendations about medical cannabis.
With spring training now in full swing, Major League Baseball is further clarifying its stance on marijuana. Players can now consume cannabis without risk of discipline, the league explained in a new memo, but they can’t show up to work under the influence and—at least for now—are barred from entering into commercial arrangements with companies in the marijuana industry.
Texas is one step closer to joining the 34 states where medicinal marijuana is legal after state legislators passed a law written by North Texas Republican representative and registered nurse Stephanie Klick to expand the conditions that can be treated with medicinal cannabis. Although the law narrowly defines which conditions can be treated with medicinal marijuana, it is a significant expansion.
Cannabis use among inflammatory bowel disease (IBD) patients is common. There are many studies of various laboratory models demonstrating the anti-inflammatory effect of cannabis, but their translation to human disease is still lacking.
It contains approximately 540 natural compounds including more than 100 that have been identified as phytocannabinoids due to their shared chemical structure. The predominant psychotropic component is Δ9-tetrahydrocannabinol (Δ9-THC), while the major non-psychoactive ingredient is cannabidiol (CBD).
Alcohol use contributes significantly to the risk of all-cause mortality, being the major risk factor for premature death and disability among adults worldwide.
The opioid epidemic has spurred investigations for nonopioid options, yet limited research persists on medical marijuana’s (MMJ) efficacy in managing cancer-related symptoms.
An Australian company is 3D-printing hemp bioplastic walls, floors and roofs to be used in the construction of eco-friendly prefabricated homes.